The report entitled; “Nuclear Medicine Imaging Equipment Market, Trends, Dynamics, and Market Analysis,” recently published by Stratview Research offers a comprehensive outlook of the industry. This report by Type (SPECT Systems, Hybrid PET Systems, Planar Scintigraphy), Application (Oncology, Cardiology, Others), End-User (Hospitals, Imaging Centers, Academic and Research Centers, Others), and Region - COVID-19 Impact Analysis and Forecast to 2026.
Nuclear Medicine Imaging Equipment Market Insights:
The Nuclear Medicine Imaging Equipment Market is projected to grow from USD 2.8 billion in 2020 to USD 3.7 billion by 2026 at a CAGR of around 4.9% during the forecast period.
Key Players
The report also highlights the topmost linchpins active in the market. According to the list, here are few key players mentioned in the report –
Key players operating in the Nuclear Medicine Imaging Equipment Market are:
- Digirad Corp. (US)
- GE Healthcare Plc (UK)
- Mediso Medical Imaging Systems (Hungary)
- Philips Healthcare (US)
- Positron Corporation (US)
- Siemens Healthineers (Germany)
- DDD-Diagnostic A/S (Denmark)
- CMR Naviscan Corporation (US)
- Surgiceye GmbH (Germany)
- Canon Medical Systems Corporation (Japan)
- Neusoft Medical Systems Co., Ltd. (China).
Market Segmentation:
The report segments based upon geographics, demographics, benefits and volume etc., identifies the most attractive segments and sub-segments and have different driving factors. The segmentation mentioned in the report has been arranged in such a way that it can help users to be more efficient in terms of time, investment, and other resources. It also allows the businesses to learn more about their target audience so that they can tailor their strategies, and campaigns in increasing their market share and revenue.
By application, the nuclear medicine imaging equipment market has been bifurcated into oncology, cardiology, and others. The cardiology segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to increasing product use in evaluating coronary heart disease (CHD) and cardiomyopathy.
By region, the North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to the growing emphasis on the adoption of advanced diagnostic tools in the healthcare industry coupled with the presence of key market players such as Digirad Corp. (US) and Philips Healthcare (US). The market growth in Asia-Pacific is expected to be driven by an increasing number of people suffering from cancer and heart-related diseases in developing countries particularly China and India.
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
